Cardiff's Velindre Cancer Centre — Wales's principal cancer treatment centre — manages myeloma and lymphoma patients from across South and Mid Wales requiring Bortezomib-based combination regimens. Bortenat 3.5mg from Unnati Pharmax provides Velindre's pharmacy with a cost-effective, WHO-GMP certified alternative to brand Velcade for institutional procurement.
Welsh patients with multiple myeloma are managed under protocols jointly developed by Cardiff's haematology team and the All Wales Medicines Strategy Group (AWMSG). For patients accessing private treatment or those in clinical trials requiring self-funded supply, generic Bortenat provides significant cost savings without compromising the clinical standard Velindre's patients expect.
Visit medshopy.com or WhatsApp +91 82650 41513.
Welsh patients with multiple myeloma are managed under protocols jointly developed by Cardiff's haematology team and the All Wales Medicines Strategy Group (AWMSG). For patients accessing private treatment or those in clinical trials requiring self-funded supply, generic Bortenat provides significant cost savings without compromising the clinical standard Velindre's patients expect.
Visit medshopy.com or WhatsApp +91 82650 41513.
What is the difference between the VRd and CVD (CyBorD) myeloma regimens, and when is each used?Both VRd (Bortezomib + Lenalidomide + dexamethasone) and CyBorD/CVD (Cyclophosphamide + Bortezomib + dexamethasone) are Bortezomib-containing induction regimens for newly diagnosed myeloma, but they differ in the third drug. VRd includes Lenalidomide, making it a more comprehensive regimen with superior depth of response and overall survival data — it's generally preferred for transplant-eligible patients. CyBorD uses Cyclophosphamide instead, which is less expensive, doesn't require the REMS restrictions of Lenalidomide, and has a slightly different toxicity profile. CyBorD is often chosen when Lenalidomide is less accessible, in patients with renal impairment (where Lenalidomide requires dose adjustment), or in specific clinical trial contexts. Cardiff's haematologists select between them based on patient-specific factors.
